Persistence Of Valvulopathy In The Camellia-Timi 61 Trial Of Lorcaserin In Obese Or Overweight Patients At Increased Cardiovascular Risk

Christina Fanola,Erin Bohula,Neil Weissman,Stephen Wiviott,Arman Qamar,Julia Kuder,KyungAh Im,Silvio Inzucchi,Darren McGuire,Anthony Keech,Steven Smith,Carlos Perdomo,Wenfeng Miao,Tushar Patel,Marc Sabatine,Benjamin M. Scirica

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2019）

引用 0|浏览55

暂无评分

摘要

Lorcaserin, a serotonin 2C receptor agonist, recently demonstrated sustained weight loss without an increased risk of cardiovascular (CV) events or valvulopathy in obese or overweight pts at high CV risk. Here we evaluate the persistence of valvulopathy measures. The CAMELLIA-TIMI 61 trial

查看译文

关键词

lorcaserin,valvulopathy,cardiovascular risk,overweight patients,camellia-timi

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要